In short: Popped 10% on early PE buyout interest (EQT, Advent) — a cash-generative European molecular-testing name that sold to $33 in May (Jan peak $56, now $41); a ~$50 bid = ~20% upside. Just starting work; needs the bid substantiated.
Qiagen is a European medical-testing company that reliably generates cash. It jumped 10% on rumors that two big private-equity firms (EQT and Advent) are circling it. It had already fallen hard — from $56 in January to $33 in May, now $41 — so a buyout around $50 would be about 20% upside. Singh is intrigued but honest that it's just a rumor: he's "starting our work" and needs to confirm a real bid before taking a position.
Full passage: premium transcript (PDF).
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.